Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06669571 In Subjects With Idiopathic Parkinson's Disease

Next Previous
Trial Profile

A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06669571 In Subjects With Idiopathic Parkinson's Disease

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PF 6669571 (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 24 Feb 2018 Primary endpoint (Maximum percent change from baseline in Movement Disorder Society-sponsor revision of the Unified Parkinsons Disease Rating Scale (MDS UPDRS) Part III at Day 7.) has not been met as per the the results published in the Clinical Drug Investigation.
  • 24 Feb 2018 Results published in the Clinical Drug Investigation
  • 08 Jul 2016 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top